{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-24-000030","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.004633+00:00","generated_at":"2026-05-30T03:20:36.144555+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prestige Consumer Healthcare Q2 revenue $283.8M, diluted EPS $1.09; reaffirms FY2025 outlook","bullets":["Revenue $283.8M (-0.9% YoY) slightly ahead of expectations; diluted EPS $1.09 vs $1.07 prior year.","North American OTC down 1.9% to $239.8M; International OTC up 5.0% to $44.0M driven by Hydralyte.","Free cash flow $67.8M in Q2; net cash from operations $69.8M, up 11.7% YoY.","Repurchased ~0.2M shares for $12M in Q2; reduced debt by $75M YTD; leverage ratio 2.7x.","Reaffirmed FY2025 outlook: revenue $1,125-1,140M, adj. diluted EPS $4.40-4.46, free cash flow $240M+."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-24-000030","json":"https://secwatch.observer/filing/0001295947-24-000030.json","markdown":"https://secwatch.observer/filing/0001295947-24-000030.md","text":"https://secwatch.observer/filing/0001295947-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594724000030/0001295947-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594724000030/pbh-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:20:36.144555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}